JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



First published online January 15, 2010, 10.2967/jnumed.109.070672
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.109.070672v1
51/2/193    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Rominger, A.
Right arrow Articles by Hacker, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rominger, A.
Right arrow Articles by Hacker, M.
Journal of Nuclear Medicine Vol. 51 No. 2 193-197
© 2010 by Society of Nuclear Medicine
doi: 10.2967/jnumed.109.070672

Clinical Investigation

In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors

Axel Rominger1, Tobias Saam2, Eva Vogl1, Christopher Übleis1, Christian la Fougère1, Stefan Förster1, Alexander Haug1, Paul Cumming1, Maximilian F. Reiser2, Konstantin Nikolaou2, Peter Bartenstein1 and Marcus Hacker1

1 Department of Nuclear Medicine, University of Munich, Munich, Germany; and 2 Institute of Clinical Radiology, University of Munich, Munich, Germany

Correspondence: For correspondence or reprints contact: Marcus Hacker, Department of Nuclear Medicine, University of Munich, Marchioninistrasse 15, 81377 München, Germany. E-mail: marcus.hacker{at}med.uni-muenchen.de

We measured the uptake of the somatostatin receptor ligand 68Ga-[1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid]-D-Phe1,Tyr3-octreotate (DOTATATE) in the left anterior descending coronary artery (LAD) in association with calcified plaques (CPs) and cardiovascular risk factors. Methods: Seventy consecutive tumor patients were examined by whole-body 68Ga-DOTATATE contrast-enhanced PET/CT. Blood-pool–corrected standardized uptake value (target-to-background ratio) was measured in the LAD, and CT images were used to detect CP. Cardiovascular risk factors and history of prior cardiovascular events were recorded. Results: 68Ga-DOTATATE uptake was detectable in the LAD of all patients. Target-to-background ratio in the LAD correlated significantly with the presence of CP (R = 0.34; P < 0.01), prior vascular events (R = 0.26; P < 0.05), and male sex (R = 0.29; P < 0.05), whereas CP correlated with these parameters but also with age (R = 0.34; P < 0.01) and hypertension (R = 0.25; P < 0.05). Conclusion: In a series of oncologic patients, those with prior cardiovascular events and calcified atherosclerotic plaques showed significantly increased 68Ga-DOTATATE uptake in the LAD, suggesting a potential role of this tracer for plaque imaging in the coronary arteries.

Key Words: atherosclerosis • plaque imaging • 68Ga-DOTATATE PET/CT • cardiovascular • coronary arteries

COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2010 51: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2010 by the Society of Nuclear Medicine.